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Abstract: This case reports on the successful maternal to fetal transfer of neutralizing antibodies after
vaccination with BNT162b2 in a pregnant woman at 25 weeks of gestation. The levels of neutralizing
antibodies were approximately 5-fold higher in the umbilical cord than in the maternal blood while
the level of total antibodies showed only a 2-fold increase. This suggest that the antibodies that
crossed the syncytiotrophoblast cell barrier have specific characteristics that correlate to functional
neutralizing capacity. Although pregnant and lactating women have been excluded from clinical
trials for several reasons including ethical concerns about fetal exposure, accumulating evidence has
now revealed that these vaccines are safe and efficient for both the fetus and the woman. Vaccination
against COVID-19 in pregnancy is vital to control disease burden and to decrease morbidity in
the ante-, peri- and post-natal periods. Inclusion of pregnant women in research programs for the
development of SARS-CoV-2 vaccines should be mandatory to provide this population with the
equitable benefits of vaccine research.
Keywords: neonates; infant; COVID-19; vaccine; antibodies; pregnancy; immunity
1. Introduction
Before the vaccine rollout, multiple cohort studies documented that pregnant
woman were more susceptible to severe COVID-19 compared to age-matched non-
pregnant women [1–3]. This is in line with the initial expectations, which stated that
according to immunologic and cardiopulmonary adaptations occurring during preg-
nancy, the risk of severe illness from respiratory infections typically increases [4]. A
systematic review of 60 studies on SARS-CoV-2 in pregnancy reported that severe illness
occurred in up to 18% of pregnant patients and critical disease complicated up to 5%
of the cases, comparable to rates observed in the general population [5]. Nevertheless,
despite recommendations from public health advocates for pregnant women including
the Center for Disease Control and Prevention (CDC), the American College of Obstetri-
cians and Gynecologists (ACOG), and the American Academy of Pediatrics, pregnant or
breastfeeding women have been excluded from clinical trials during the development of
existing COVID-19 vaccines [6–12]. This causes large gaps in understanding the safety
and efficacy of these vaccines in this population, which can be definitively detrimental to
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vaccine acceptance. Although data are emerging documenting the efficacy and the safety
of these vaccines [13] and although guidance from these data recommend vaccination in
pregnant and breastfeeding women, [14–16] getting vaccinated during pregnancy mainly
remains a personal choice. Thus, the acceptance of COVID-19 vaccination in pregnancy
is an important concern. According to a survey study, the COVID-19 vaccine acceptance
rate during pregnancy was 58.4%, a rate which is consistent with the acceptance rate of
other recommended vaccines in pregnancy but that is not sufficient to avoid deleterious
cases of neonate infection due to maternal to fetal transmission or infection during the
early stages of life [17,18].
Both neonates and pregnant women are particularly susceptible to respiratory in-
fections, including influenza and respiratory syncytial virus (RSV) [19–21], and recent
data demonstrate that a greater proportion of neonates and infants have severe or critical
illness upon SARS-CoV-2 infection compared to older children [22–24]. Rare cases of
vertical transmission have been reported in neonates [5], but histopathological changes
in the placenta have suggested that the inflammatory nature of SARS-CoV-2 infection
during pregnancy could cause adverse obstetric and neonatal events [25,26]. The risks of
SARS-CoV-2 infection during pregnancy are preterm delivery, preeclampsia, emergency
cesarian delivery, and neonatal complications including respiratory distress or pneumonia,
disseminated intravascular coagulation, asphyxia, and perinatal deaths [27,28]. In addition,
placental injury may increase the risk of long-term adverse neurodevelopmental, as is the
case for other conditions that affect the placenta through the release of proinflammatory
cytokines such as interleukin-6, which leads to the activation of T helper cell 17 [29].
Neonates rely on the transfer of maternal immunoglobulin G (IgG) across the placenta
for protection against pathogens, and vaccination aims to mimic the presence of pathogens
to stimulate the maternal immune response. Data from the literature show that maternal
to neonatal transfer of anti-SARS-CoV-2 antibodies is efficient although the maternal to
fetal transfer ratio of IgG antibodies may differ depending on gestational age and the
type of immunization, i.e., disease- or vaccine-induced [30–33]. There is also a significant
improvement in the transfer of spike specific IgG into the umbilical cord with the time from
second dose, suggesting that time from vaccination may be an important determinant of
the transfer rates of specific IgG subpopulations following immunization in pregnancy [32].
Despite reassuring data, the neutralizing capacity of these transferred antibodies was not
assessed [30,32,33].
This case-report assessed the neutralizing capacity of umbilical cord blood compared
to maternal blood in addition to conventional serological assay in a woman who received ta
two-dose regimen of BNT162b2 during the antenatal period. To appreciate the magnitude
of the antibody response of this dyad, a comparison with an age-matched cohort will also
be done.
2. Case Description and Methods
A 28-year-old pregnant woman received her first dose of BNT162b2 mRNA COVID-19
vaccine (Pfizer-BioNTech, Mainz, Germany) at 25 weeks of gestation. The second was
administered at 30 weeks. No problem was reported during the antenatal period, and no
severe adverse events were reported after the vaccination. The patient only complained
headache and tiredness the day after the second dose, which resolved with the adminis-
tration of paracetamol twice a day. The delivery was planned to be on the 4th of July but
occurred 8 days earlier, on the 26th of June at the Centre Hospitalier Régional (CHR) of Huy
(Liège, Belgium), 90 days after the administration of the first vaccine dose. No delivery
complications were reported, and all of the parameters of the newborn were normal. At
4 weeks, the newborn was still doing well. On the day of delivery, umbilical cord blood
was collected as well as maternal blood to permit comparison of the level of SARS-CoV-2
neutralizing antibodies.
To compare the results obtained with the umbilical cord and maternal blood samples,
13 non-pregnant women of a similar age (i.e., 25 to 35 years of age) with no history of
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previous SARS-CoV-2 infection (i.e., no documented positive RT-PCR and the absence of
anti-nucleocapsid antibodies), were included. These vaccinated controls were recruited
at the Clinique Saint-Luc Bouge (Namur, Belgium) due to their participation in the CRO-
VAX HCP study, a study which has already been described in detail elsewhere [34–36].
All of the participants provided informed consent prior to specimen and data collection.
The study was approved by a central ethical committee (EudraCT registration number:
2020-006149-21).
Blood samples were collected in SST™ II advanced tubes (BD Vacutainer, Plymouth,
UK) and were processed according to the manufacturer recommendations to obtain serum.
Serum samples were then aliquoted and were stored at −20 ◦C until analysis. Antibodies
against the SARS-CoV-2 nucleocapsid (anti-NCP; Elecsys Anti-SARS-CoV-2 NCP total qual-
itative ECLIA, Roche Diagnostics, Machelen, Belgium) and the receptor binding domain of
the S1 subunit of the spike protein (anti-S; Elecsys anti-SARS-CoV-2 spike total quantitative
ECLIA, Roche Diagnostics) were measured at each time point. Results above 0.8 U/mL
(manufacturer’s cut-off) or 0.165 COI (cut-off index as found previously [37]) for anti-S and
anti-NCP antibodies, respectively, were considered positives.
Neutralizing capacity was estimated by performing a surrogate virus neutralization
test (sVNT) [38]. The iFlash-2019-nCoV NAbs assay (performed on an iFlash1800 analyzer
from Shenzhen YHLO Biotech Co., Ltd. (Shenzhen, China)) is a one-step competitive
paramagnetic particle chemiluminescent immunoassay (CLIA) for the quantitative deter-
mination of 2019-nCoV NAbs in human serum and plasma. The assay detects NAbs that
block the binding of RBD and ACE2. First, NAbs (if present) react with the RBD antigen
coated on paramagnetic microparticles to form a complex. Second, the acridinium-ester-
labeled ACE2 conjugate is added to competitively bind to the RBD-coated particles that
were not neutralized by the NAbs (if present) from the sample, and these form another
reaction mixture. Under a magnetic field, magnetic particles are adsorbed to the wall of the
reaction tube, and unbound materials are washed away by the wash buffer. The resulting
chemiluminescent reaction is measured in relative light units (RLUs), with an inverse rela-
tionship between the amount of NAbs and the RLU value being detected. A result <10.0
arbitrary unit (AU)/mL is considered negative, and a result >10.0 AU/mL is considered
positive (according to the manufacturer’s information). The neutralizing capacity was also
confirmed using a pseudovirus neutralization test, as previously described [38]. Samples
are considered to be neutralizing if the dilution factor provides a 50% diminution of the
relative infectivity that is superior to 1:20. The agreement of the sVNT assay with the pVNT
was found to be 97.2% [38].
3. Results and Discussion
The total anti-RBD titers of the maternal and the umbilical cord blood were 1120 U/mL
and 2349 U/mL compared to 1747 U/mL (geometric mean; 95%CI, 1231–2438 U/mL) in the
control group at the identical time point, i.e., 90 days post-vaccination. The NAbs titers were
163 and 906 AU/mL for the maternal and the umbilical cord blood, respectively, compared
to 427 AU/mL (geometric mean; 95%CI, 222–820 AU/mL) for the control group at 90 days
post-vaccination. The maternal to fetal transfer ratio was 2.10 for total anti-RBD antibodies
and 5.56 for NAbs. A summary of the results is presented in Table 1 and Figure 1. The
neutralizing capacity of the maternal and umbilical cord blood was confirmed by the pVNT,
with both samples having higher dilution factors than 1:20 to half of the relative infectivity.
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Table 1. Summary of serological results obtained from the maternal and the umbilical cord blood samples. For pVNT, the
highest the dilution factor, the stronger the neutralizing capacity.
Serum Samples Anti-N Titer (U/mL) Anti-S Titer (U/mL) sVNT (AU/mL) pVNT (Dilution Factor)
Maternal <0.165 (negative) 1120 162.9 1/40 (positive)
Umbilical cord blood <0.165 (negative) 2349 906.4 1/60 (positive)
Maternal to fetal transfer
ratio † / 2.10 5.56 1.50
‡
† Ratio is defined as the results of umbilical cord blood divided by maternal blood. ‡ pVNT is not a calibrated quantitative method, and
thus, the ratio is only given for information. Abbreviations: pVNT, pseudovirus neutralization test; N, nucleocapsid; NR, non-reactive; S,
spike; sVNT, surrogate virus neutralization test.
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Figure 1. Serological response in controls, maternal and umbilical cord sera. Control sera selected from the CRO-VAX HCP
study cohort and included 13 non-pregnant women aged from 25 to 35 (median, 30 years of age; min–max range, 25–35),
without history of SARS-CoV-2 infection. Blood was collected at baseline (day 0), day 14, day 28, day 42, day 56, and day 90.
Maternal and umbilical cord blood were only collected on day 90 after the vaccination, at the time of delivery. Positivity
thresholds for the Roche RBD total Ab and the YHLO NAbs assays were 0.8 U/mL and 10.0 AU/mL, respectively.
Recent investigations suggested that maternal SARS-CoV-2 immunization, either in-
duced by the disease or by the vaccination, may provide neonatal protection through the
transplacental transfer of antibodies [30–33]. Of particular importance was the demon-
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stration that antibody transfer is correlated with the time from vaccination to delivery,
which may allow future determination of the optimal timing of COVID-19 vaccination in
pregnant women [33]. Compared to the non-pregnant controls, pregnant women exhibit
quite comparable vaccine-specific antibody titers, [39] although IgG titers have also been
found to be slightly lower in pregnant women [13].
Zdanowski et al. observed a slightly lower maternal to fetal ratio, i.e., 1.28 ± 0.80 [33].
Mittal et al. also report that the mean IgG titer is similar in maternal and infant sera,
but the average gestational age at first vaccine dose was 33 weeks [40]. In our case, 13
weeks separate the first vaccine dose to delivery, which could then explain the higher ratio
observed. This observation was also made by Beharier et al. and Mittal et al., and the same
phenomenon has been also reported after SARS-CoV-2 infection [30,40]. Thus, the data
in the literature are consistent and should now permit us to draw hypothesis on when to
vaccine pregnant women in order to achieve the best maternal to fetal transfer ratio. A first
BNT162b2 dose administered during the second trimester could permit high umbilical cord
neutralizing antibody titers that are even higher than the ones observed in the maternal
blood to be obtained (Table 1).
Interestingly, our case also confirms the presence of neutralizing antibodies in the
umbilical cord blood (Table 1). Another case demonstrated that the antibody subtypes,
which are transferred, possess a neutralizing capacity, although a clear description of the
neutralization assay that was used was not provided [41]. It is also interesting to note
that total antibodies and NAbs titers in the maternal blood were at the lower range in our
control cohort (Figure 1). This may be due to individual factors or may be the consequence
of the maternal to fetal transfer of IgG antibodies, reducing the level of antibodies in the
maternal blood.
The observations that we made in this case report following vaccination with BNT162b2
are not so surprising. For most pathogens, umbilical cord titers of IgG are higher than in
maternal blood due to endosomal transport of IgG across the syncytiotrophoblast cell bar-
rier from maternal to fetal circulation [42–44]. Among these IgG antibodies, galactosylated
IgG1 antibodies are transferred preferentially, followed by IgG3, IgG2, and IgG4 [45]. This
is potentially the result of enhanced binding to both placental FcRN and FCGR3, enabling
the selective transfer of specific antibody subpopulations to most effectively arm neonates
in the setting of pathogen exposure [45,46]. The fact that the ratio for neutralizing anti-
bodies is higher than the one of total antibodies may also be explained by this preferential
transfer of IgG1, as most serological assays used to assess the humoral response towards
SARS-CoV-2 vaccination target either all types of antibodies or all IgG subtypes. Indeed, it
is possible that specific Fc glycoforms can be linked to Fab specificity and subsequently to a
different neutralizing capacity, as reported for influenza vaccination [47]. Thus, if a specific
fraction of neutralizing galactosylated IgG subtypes is transferred from the maternal blood
to the fetus, the neutralizing capacity ratio may increase more sharply than the total level
of antibodies since other types of antibodies, which are not neutralizing and do not transfer
trough the placenta, can compensate for the decrease of neutralizing antibodies in the
maternal blood.
Interestingly, in line with the above explanations, immunization transfer may also
depend on whether it is acquired after vaccination or previous infection. Indeed, some
cases were reported and described inefficient maternal to fetal transfer following COVID-19
disease during pregnancy [48,49]. This could have been explained by Rh isoimmunization,
which can compete for IgG transfer within the neonatal Fc receptor (FcRN), but, despite
high levels of anti-D antibodies, protective antibodies for other pathogens (i.e., rubeola
and varicella) successfully crossed the placenta [48]. This observation can be explained,
however, by changes to the Fc-glycosylation profile of the SARS-CoV-2 antibodies due to
the inflammatory state generated by SARS-CoV-2 infection [31,50].
This may influence the neutralizing capacity of the antibodies and may impact the
transfer of immunity, especially during the third trimester [31,47,50]. Nonetheless, this
perturbed placental transfer is probably dependent on the trimester, as observed across two
Vaccines 2021, 9, 907 6 of 8
independent third trimester-infection cohorts where normalized following second trimester
infection, suggesting that inflammation-induced alterations in SARS-CoV-2-specific-glycan
profiles may resolve over time from infection [31]. It remains to be known if such alterations
in Fc glycosylation are also observed after vaccination, but in any case, our results and
those from other groups [30,32,33] strongly suggest that BNT162b2 administration in the
second trimester permit the generation of a strong immune response that can be efficiently
transferred to the fetus in order to protect neonates from SARS-CoV-2 infection.
Although these data have been obtained in a small number of subjects, these are
quite reassuring, and the present case demonstrates that the antibody subtypes that are
transferred possess high neutralizing capacity.
4. Conclusions
This case reports on the successful maternal to fetal transfer of neutralizing antibodies
after vaccination with BNT162b2 in a pregnant woman at 25 weeks of gestation. The levels
of neutralizing antibodies were approximately 5-fold higher in the umbilical cord than
in the maternal blood, while the level of total antibodies showed only a 2-fold increase.
This suggests that the antibodies that crossed the syncytiotrophoblast cell barrier have
specific characteristics that correlate to functional neutralizing capacity. Although pregnant
and lactating woman have been excluded from clinical trials for several reasons including
ethical concerns about fetal exposure, accumulating evidence has now revealed that these
vaccines are safe and efficient for both the fetus and the woman. Vaccination against
COVID-19 in pregnancy is vital to control disease burden and to decrease morbidity in the
ante-, peri- and post-natal periods. Inclusion of pregnant women in research programs for
the development of SARS-CoV-2 vaccines should be mandatory to provide this population
with the equitable benefits of vaccine research.
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